ALPIX Stock Overview
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application.
Pixium Vision Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€0.51|
|52 Week High||€1.33|
|52 Week Low||€0.48|
|1 Month Change||3.61%|
|3 Month Change||-22.31%|
|1 Year Change||-49.04%|
|3 Year Change||-65.97%|
|5 Year Change||-92.20%|
|Change since IPO||-93.72%|
Recent News & Updates
|ALPIX||FR Medical Equipment||FR Market|
Return vs Industry: ALPIX underperformed the French Medical Equipment industry which returned -5.8% over the past year.
Return vs Market: ALPIX underperformed the French Market which returned -5.9% over the past year.
|ALPIX Average Weekly Movement||5.2%|
|Medical Equipment Industry Average Movement||7.0%|
|Market Average Movement||5.9%|
|10% most volatile stocks in FR Market||10.0%|
|10% least volatile stocks in FR Market||3.4%|
Stable Share Price: ALPIX is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ALPIX's weekly volatility (5%) has been stable over the past year.
About the Company
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat bilndness, which replace the normal physiological function of the eye’s photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the visual information to the brain via the optic nerve. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC.
Pixium Vision Fundamentals Summary
|ALPIX fundamental statistics|
Is ALPIX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALPIX income statement (TTM)|
|Cost of Revenue||€0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.19|
|Net Profit Margin||-610.27%|
How did ALPIX perform over the long term?See historical performance and comparison
Is Pixium Vision undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALPIX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALPIX's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: ALPIX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French Medical Equipment industry average.
PE vs Market: ALPIX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALPIX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALPIX is overvalued based on its Price-To-Book Ratio (5.1x) compared to the FR Medical Equipment industry average (2.2x).
How is Pixium Vision forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALPIX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALPIX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALPIX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALPIX's revenue is expected to decline over the next 3 years (-35.5% per year).
High Growth Revenue: ALPIX's revenue is forecast to decline over the next 3 years (-35.5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALPIX's Return on Equity is forecast to be high in 3 years time
How has Pixium Vision performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALPIX is currently unprofitable.
Growing Profit Margin: ALPIX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALPIX is unprofitable, but has reduced losses over the past 5 years at a rate of 5.5% per year.
Accelerating Growth: Unable to compare ALPIX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALPIX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.5%).
Return on Equity
High ROE: ALPIX has a negative Return on Equity (-187.99%), as it is currently unprofitable.
How is Pixium Vision's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ALPIX's short term assets (€16.9M) exceed its short term liabilities (€6.5M).
Long Term Liabilities: ALPIX's short term assets (€16.9M) exceed its long term liabilities (€7.3M).
Debt to Equity History and Analysis
Debt Level: ALPIX has more cash than its total debt.
Reducing Debt: ALPIX's debt to equity ratio has increased from 6.1% to 139.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALPIX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALPIX has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 12.1% each year.
What is Pixium Vision current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALPIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALPIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALPIX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALPIX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALPIX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Lloyd Diamond (53 yo)
Mr. Lloyd Diamond is the Chief Executive Officer at Pixium Vision SA since May 13, 2019 and serves as its Director since May 29, 2019. He was the Chief Business Officer of BONESUPPORT AB since January 22,...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Lloyd's total compensation is reasonable compared to companies of similar size in the French market.
Compensation vs Earnings: Insufficient data to compare Lloyd's compensation with company performance.
Experienced Management: ALPIX's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Experienced Board: ALPIX's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.8%.
Pixium Vision SA's employee growth, exchange listings and data sources
- Name: Pixium Vision SA
- Ticker: ALPIX
- Exchange: ENXTPA
- Founded: 2011
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €29.874m
- Shares outstanding: 58.58m
- Website: https://www.pixium-vision.com
Number of Employees
- Pixium Vision SA
- 74 rue du Faubourg Saint-Antoine
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/27 00:00|
|End of Day Share Price||2022/05/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.